Sienna Biopharm (NASDAQ:SNNA) insider Paul F. Lizzul acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $150,000.00. Following the acquisition, the insider now owns 94,634 shares in the company, valued at $1,419,510. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Sienna Biopharm (SNNA) traded up 1.73% during mid-day trading on Friday, hitting $19.38. 76,768 shares of the company were exchanged. Sienna Biopharm has a 12-month low of $18.50 and a 12-month high of $21.20.
TRADEMARK VIOLATION WARNING: This piece was published by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://rinconhillneighbors.org/2017/08/19/paul-f-lizzul-buys-10000-shares-of-sienna-biopharmaceuticals-inc-snna-stock-updated-updated.html.
Sienna Biopharm Company Profile
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with our FREE daily email newsletter.